Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neoplasm
100%
Non Small Cell Lung Cancer
54%
Disease
53%
Computer Assisted Tomography
51%
Surgery
50%
Recurrent Disease
47%
Malignant Neoplasm
46%
Overall Survival
44%
Lung Cancer
42%
Magnetic Resonance Imaging
37%
Adverse Event
34%
Breast Cancer
32%
Systematic Review
31%
Retrospective Study
30%
Lung Transplantation
28%
Epidermal Growth Factor Receptor
28%
Hepatocellular Carcinoma
27%
Radiofrequency Ablation
26%
Bleeding
25%
Metastatic Carcinoma
25%
Symptom
24%
Meta-Analysis
24%
Biopsy
24%
Hazard Ratio
24%
Diagnosis
23%
Stomach Cancer
22%
Odds Ratio
22%
Radiation Therapy
21%
Chemoradiotherapy
21%
Prognostic Factor
21%
Cancer Cell
21%
Observational Study
21%
Pediatrics
21%
Prostate Cancer
20%
Survival Rate
20%
Cisplatin
18%
Quality of Life
18%
Multivariate Analysis
17%
Knee
17%
Transitional Cell Carcinoma
17%
Immune Checkpoint Inhibitor
17%
Biological Marker
17%
Elderly Patient
16%
Infection
16%
Arm
15%
Randomized Controlled Trial
15%
Injury
15%
Progression Free Survival
15%
Clinical Trial
15%
Atrial Septal Defect
15%
Clear Cell Renal Cell Carcinoma
14%
Lymph Node
14%
Aneurysm
13%
Cholestasis
13%
Cohort Analysis
13%
Esophageal Cancer
13%
Combination Therapy
13%
Endoscopic Ultrasound
13%
Lymph Node Metastasis
13%
Diabetes Mellitus
12%
Embolization
12%
Prevalence
12%
Prospective Study
12%
Diabetic Nephropathy
12%
Prospective Cohort Study
12%
Neoadjuvant Chemotherapy
12%
Liver Transplantation
12%
Programmed Cell Death
11%
Cross Sectional Study
11%
Surgeon
11%
Suture Material
11%
Small Cell Lung Cancer
11%
Cystectomy
11%
Nivolumab
11%
Adenocarcinoma
10%
In Vitro
10%
Recurrence Free Survival
10%
Retrospective Cohort Study
10%
Pancreas Cancer
10%
Catheter Ablation
10%
Retroperitoneal Lymph Node Dissection
10%
Surgical Technique
10%
Hepatectomy
10%
Ulcerative Colitis
10%
Cancer
10%
COVID-19
9%
Apoplexy
9%
Cryoablation
9%
Lung Metastasis
9%
Gastrectomy
9%
Pulmonary Hypertension
9%
Logistic Regression Analysis
9%
Artery
9%
Positron Emission Tomography-Computed Tomography
9%
Body Mass Index
9%
Cancer Therapy
9%
Postoperative Complication
9%
Lung Tumor
9%
Urinary System
9%
Lymphocyte
9%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
73%
Neoplasm
67%
Chemotherapy
66%
Malignant Neoplasm
60%
Lung Cancer
55%
Disease
47%
Epidermal Growth Factor Receptor
46%
Overall Survival
40%
Mouse
36%
Adverse Event
34%
Cisplatin
33%
Liver Cell Carcinoma
25%
Breast Cancer
24%
Progression Free Survival
23%
Recurrent Disease
22%
Combination Therapy
20%
Symptom
19%
Clinical Trial
18%
Biological Marker
18%
Immune Checkpoint Inhibitor
18%
Chemoradiation Therapy
17%
Small Cell Lung Cancer
17%
Prostate Cancer
17%
Infection
16%
Observational Study
16%
Inflammation
16%
Mouse Model
15%
Protein P53
14%
Docetaxel
14%
Randomized Controlled Trial
14%
Retrospective Study
13%
Gefitinib
13%
Survival Rate
13%
Stomach Cancer
12%
Monotherapy
12%
Diabetes Mellitus
11%
Gamma Urogastrone
11%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
Paclitaxel
11%
Cytokine
11%
Cohort Study
11%
Pancreas Cancer
10%
Adenoviridae
10%
Remission
10%
Tumor Growth
9%
Prevalence
9%
Diabetic Nephropathy
9%
Telomerase
9%
Lung Adenocarcinoma
9%
Pembrolizumab
9%
Trastuzumab
9%
Ulcerative Colitis
8%
Protein Tyrosine Kinase Inhibitor
8%
Syndrome
8%
Oncolytic Adenovirus
8%
Doxorubicin
8%
Alzheimer's Disease
8%
Esophagus Cancer
8%
Crohn's Disease
8%
Transitional Cell Carcinoma
7%
Gemcitabine
7%
Metastatic Breast Cancer
7%
Epidermal Growth Factor Receptor 2
7%
Prospective Study
7%
microRNA
7%
Afatinib
7%
Bladder Cancer
7%
Disease Exacerbation
7%
Etoposide
7%
Osimertinib
7%
Anaplastic Lymphoma Kinase
7%
Irinotecan
7%
Therapeutic Effect
7%
Receptor
7%
Chronic Kidney Failure
7%
Alectinib
7%
Renal Cell Carcinoma
7%
Nonalcoholic Fatty Liver
7%
Carboplatin
7%
Lymph Node Metastasis
7%
Cyclophosphamide
7%
Bleeding
7%
Vasculotropin
6%
Tumor Necrosis Factor
6%
Coronavirinae
6%
Antioxidant
6%
Colorectal Cancer
6%
Nivolumab
6%
Periodontitis
6%
Inflammatory Bowel Disease
6%
Injury
6%
Recurrence Free Survival
6%
Non Muscle Invasive Bladder Cancer
6%
Creatinine
6%
Non Insulin Dependent Diabetes Mellitus
6%
Systemic Lupus Erythematosus
6%
Median Survival Time
6%
Pulmonary Hypertension
6%
Virotherapy
6%
Prospective Cohort Study
6%
Keyphrases
Japan
27%
Non-small Cell Lung Cancer (NSCLC)
23%
Confidence Interval
20%
Overall Survival
16%
Tumor
15%
Lung Cancer
13%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
13%
Okayama
11%
Cisplatin
11%
Hazard Ratio
11%
Lung Transplantation
10%
EGFR mutation
10%
Prognostic Factors
10%
Chemotherapy
10%
Immune Checkpoint Inhibitors
10%
Clinical Outcomes
9%
Risk Factors
9%
Medial Meniscus Posterior Root Tear
8%
Japanese Patients
8%
Elderly Patients
7%
Progression-free Survival
7%
Epidermal Growth Factor Receptor
7%
Hepatocellular Carcinoma
7%
Radiofrequency Ablation
7%
Adverse Events
7%
Phase II Study
6%
Odds Ratio
6%
Meta-analysis
6%
Docetaxel
6%
Breast Cancer
6%
Programmed Death-ligand 1 (PD-L1)
5%
Systematic Meta-analysis
5%
Multivariate Analysis
5%
Adenovirus
5%
Telomerase
5%
Computed Tomography
5%
Oxidative Stress
5%
Small Cell Lung Cancer
5%
Glomerular Basement Membrane
5%
Combination Therapy
5%
Cancer-associated Fibroblasts
5%
Non-small Cell Lung Cancer Patients
5%